Improving medication prescription through a pharmacist-led educational intervention and audit & feedback approach in primary care for patients over 65 years of age

A pharmacist-led educational intervention and audit and feedback approach to reduce inappropriate medication prescriptions in primary care for patients over 65 years of age

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14449434

Enrollment

170

Registered

2024-12-11

Start date

2025-05-10

Completion date

Unknown

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inappropriate prescription (benzodiazepines, proton pump inhibitors and antipsychotics for patients with dementia) in patients over 65 years old Other

Interventions

The method of randomization is simple random sampling. The unit of randomization will be the General Practitioner (GP). They will be randomly assigned to either the control or intervention group in a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All GPs with assigned patients in their primary health care center will be included

Exclusion criteria

Exclusion criteria: Does not meet the inclusion criteria

Design outcomes

Primary

Measure	Time frame
Potentially inappropriate medication prescription (benzodiazepines, proton pump inhibitors, and antipsychotics in patients diagnosed with dementia) in patients over 65 years old, measured using the number of prescriptions extracted from the e-prescription databases of each health district at 12-month follow-up.	—

Secondary

Measure	Time frame
1. The proportion of patients over 65 years old using benzodiazepines, measured using the number of prescriptions from the N05BA (diazepam, chlordiazepoxide, potassium clorazepate, lorazepam, bromazepam, clobazam, ketazolam, alprazolam, halazepam, pinazepam, clotiazepam, bentazepam), N05CD (flurazepam, flunitrazepam, triazolam, lormetazepam, midazolam, brotizolam, quazepam, lorprazolam) and N05CF (zopiclone, zolpidem, zaleplon) groups of the Anatomical Therapeutic Chemical (ATC) Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. 2. The proportion of patients over 65 years old using proton pump inhibitors for more than 8 weeks with indications other than Barrett's esophagus, severe esophagitis C or D, peptic ulcer disease, history of bleeding peptic ulcer, or concomitant prescription of NSAIDs, antiplatelet agents, anticoagulants, or corticosteroids, measured using the number of prescriptions from the A02BC (proton pump inhibitors) group of the ATC Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. 3. The proportion of patients over 65 years old with a diagnosis of dementia using antipsychotics, measured using the number of prescriptions from the N05A (antipsychotics) and N05AX (other antipsychotics) groups of the ATC Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. Added 08/05/2025: 4. The reach, engagement, adoption, fidelity and maintenance of the intervention. Reach will be defined as the percentage of participating GPs relative to the total number of eligible GPs. Engagement will measure the degree of active involvement in the intervention, including use of the feedback reports, participation in pharmacist-led sessions, and integration of recommendations into clinical practice. Adoption will be measured at the organizational level as the percentage of healthc	—

Measure

Time frame

1. The proportion of patients over 65 years old using benzodiazepines, measured using the number of prescriptions from the N05BA (diazepam, chlordiazepoxide, potassium clorazepate, lorazepam, bromazepam, clobazam, ketazolam, alprazolam, halazepam, pinazepam, clotiazepam, bentazepam), N05CD (flurazepam, flunitrazepam, triazolam, lormetazepam, midazolam, brotizolam, quazepam, lorprazolam) and N05CF (zopiclone, zolpidem, zaleplon) groups of the Anatomical Therapeutic Chemical (ATC) Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. 2. The proportion of patients over 65 years old using proton pump inhibitors for more than 8 weeks with indications other than Barrett's esophagus, severe esophagitis C or D, peptic ulcer disease, history of bleeding peptic ulcer, or concomitant prescription of NSAIDs, antiplatelet agents, anticoagulants, or corticosteroids, measured using the number of prescriptions from the A02BC (proton pump inhibitors) group of the ATC Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. 3. The proportion of patients over 65 years old with a diagnosis of dementia using antipsychotics, measured using the number of prescriptions from the N05A (antipsychotics) and N05AX (other antipsychotics) groups of the ATC Classification System code, extracted from the e-prescription databases of each health district at 12-month follow-up. Added 08/05/2025: 4. The reach, engagement, adoption, fidelity and maintenance of the intervention. Reach will be defined as the percentage of participating GPs relative to the total number of eligible GPs. Engagement will measure the degree of active involvement in the intervention, including use of the feedback reports, participation in pharmacist-led sessions, and integration of recommendations into clinical practice. Adoption will be measured at the organizational level as the percentage of healthc

—

Countries

Spain

Contacts

Public ContactAlfonso Leiva

aleiva@ibsalut.es+34 (0)971 17 58 97

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 22, 2026